NLSInvest – NLSDays: Why returning on a regular basis?

Gedea’s ambition is to develop the first antibioticfree treatment that both prevents and treats bacterial vaginosis. How far have you come on this mission?
– Bacterial vaginosis is a vaginal infection with a prevalence of 10-30% in adult women. The infection causes disturbing symptoms that affects daily life in many ways. We recently published an article about our clinical study showing that 82% of the women who received pHyph were clinically cured after 7 days and the promising data indicating that pHyph can exert a protective effect on recurrence of the condition. Thus, we are not only in a position to hopefully offering a superior treatment, we also do it in a sustainable way by replacing the need for antibiotics in the first place. We recently initiated a larger clinical trial, NEFERTITI, with a longer follow-up period to further strengthen the data and we are approaching European market approval for pHyph during this year.

You have participated in NLSDays several times, what has brought you back again and again?
– NLSDays is a great arena for us to stay up to date with our existing network of collaborators, investors and partners. As it is the largest regional partnering meeting it is also an important chance to connect with new possible collaborators and partners.

What are your expectations ahead of this very first digital version of NLSDays and NLSInvest?
– It’s a great opportunity for us to be among the selected companies and we have high expectations for the NLSDays and NLSInvest. Business partnering meetings are very important to us as we are approaching market approval and I’m glad the meeting takes place in a digital form now. The digital meetings we’ve participated in during the last year have exceeded expectations.